Targeting breast cancer using retinoic acid trifloromethyl chalcone: A promising therapeutic strategy in the treatment of breast cancer
Abstract
The study was devised to investigate the effect of retinoic acid trifloromethyl chalcone (RAFC) on mammary carcinogenesis in female rats. The data revealed a significant decrease in number of rats with mammary tumor, number of tumors per rat and tumor volume by 54, 72 and 75% respectively in RAFC group compared to control group. The ibuprofen treated rats also showed a significant decrease in number of rats with tumor, number of tumors per rat and tumor volumes by 43, 55, and 59%, respectively. Treatment of rats with RAFC also increased the latency period of tumor induction significantly. Median detection period (50% of tumors) was 92, 83 and 56 days respectively in the rats from RAFC, ibuprofen and control groups respectively after DMBA induction. These results demonstrate that RAFC possesses strong chemopreventive activity against mammary carcinogenesis.
Introduction
In Western countries breast cancer is a most frequent malignant neoplasm among women. There were 234,580 new breast cancer cases detected and 40,030 estimated deaths in the United States alone in 2013 (Siegel et al., 2013). Despite intensive cancer control efforts, it remains the second leading cause of cancer deaths among American women (Singletary et al., 1998). The main cause of death in these patients was its metastases at distant sites. Owing to difficulty in predicting metathesis development many women are over-treated and suffer toxic side effects of chemotherapy (Weigelt et al., 2005). Recent epidemiological studies suggested the presence of an inverse association between regular intake of NSAIDs and the relative risk of breast cancer (Harris et al., 2005; Harris et al., 1995; Harris et al., 1996). Animal studies have also demonstrated the effects of NSAIDs against mammary carcinogenesis (Lee et al., 1992; McCormick et al., 1995), and in our laboratories, the common over-the-counter compound ibuprofen produced highly significant reductions in tumor size and tumor burden associated with inhibition of the genetic expression of COX isoforms (Joarder et al., 1997; Robertson et al., 1998; Alshafie et al., 1999).
Regulation of cell cycle behaviour is well known by retinoids and related compounds like all-trans retinoic acid (Krupitza et al., 1995; Defer et al., 1997). Despite of the biological promise of RA to treat breast cancer (Huang et al., 1988), head and neck cancer (Lehman et al., 1988), ovarian adenocarcinoma (Szuts et al., 1991), human malignant gliomas (Jeong et al., 2006), and acute promyelocytic leukemia (Chung et al., 2012), its poor aqueous solubility (0.1 µM at pH 7.3) (Crocetti et al., 2012; Tanaka et al., 2013) under in vivo restricts its clinical applications. One of the techniques to overcome this drawback is the development of polymeric micelles (Stummeret al., 2009), like glycol chitosan micelle. RA-incorporated GC nanoparticles inhibit the proliferation of HuCC-T1 cholangiocarcinoma cells at higher than 20 μg/mL of RA concentration (Norden et al., 2006). In the present study more active anlogues of retinoic acid, retinoic acid trifloromethyl chalcone (Figure 1) was used to investigate its effect on breast cancer.
Materials and Methods
Reagents and chemicals
Retinoic acid, 7,12-dimethylbenz(a)anthracene (DMBA) and all other reagents with the highest purity were purchased from Sigma Chemical Co. (St. Louis, MO). The parent drug (retinoic acid) was then made one step modification to get its florochalcone. Ibuprofen oral suspension was purchased as Motrin (100 mg/5 mL; McNeil) oral suspension.
Dietary and tumor induction protocols
Female Sprague Dawley rats 150 in number were supplied by Laboratory Animal Services Centre at the Chinese University of Hong Kong. The rats were randomly assigned into three different groups of 50 each. The control group of rats were fed standard diet alone, those of ibuprofen group were fed standard diet containing 1,200 mg/kg body weight ibuprofen and those in RAFC group were fed standard diet containing 1,200 mg/kg body weight RAFC for 110 days. All the animals received 20 mg of DMBA intragastrically by gavage. The experiment was terminated after 15 weeks and during this period general health of rats, weight gain and food consumption were monitored. The animals were palpated twice a week for detection of mammary tumors after 28 days of DMBA treatment. The clinical parameters like number of rats with tumor, time of first tumor appearance, number of tumors per rat, relative tumor size, and location of every tumor were recorded weekly. After end of experiment, a micrometer caliper was used to measure diameter of all the tumors. From the diameter tumor volume was calculated using the formula V = 4/3 πr3. The animals were sacrificed and gross examination of stomach, kidneys, and liver was performed. All tumors, stomach and both kidneys of each rat were rejected and fixed in 10% buffered formalin. Prior to histological evaluation samples were embedded in paraffin blocks. The histological evaluation was performed using H & E staining. HPLC was used to determine the level of RAFC and ibuprofen in the serum of animals after the completion of experiment.
Statistical analysis
Descriptive statistics on body weights, tumor latency, number of rats with tumor, number of tumors per rat, and tumor volumes were examined and compared among the control, ibuprofen and RAFC groups. The statistical significance of comparisons between the three treatment groups were obtained using x2 tests, Fisher’s exact test, ANOVA, and multiple mean comparison procedures (Elston et al., 1994).
Results
There was no significant difference in the initial and final average body weight of animals of control, ibuprofen and RAFC groups (Table I).
Table I: Initial and final body weight of HPDH and ibuprofen treated rats
| Group | Initial weight (g)a,b | Final weight (g)b,c |
|---|---|---|
| Control | 166.3 ± 1.7 | 281.1 ± 2.4 |
| RAFC | 169.8 ± 1.5 | 283.6 ± 2.6 |
| Ibuprofen | 167.5 ± 2.9 | 281.7 ± 1.3 |
| aMean weight ± SE; bNo significant statistical variation was observed in the means of treatment; (initial weights; p=0.17; final weights, p=0.32) | ||
The histopathological evaluation of the tumors excised from the rats of control, ibuprofen and RAFC group showed that all the 150 tumors from control and 72 tumors from ibuprofen groups were adenocarcinomas. Among 22 tumors from RAFC group, 17 were adenocarcinomas, and 3 were non-malignant fibroadenomas (Figure 2).
Figure 1: Structure of retinoic acid ifloromethylchalcone
Figure 2: Adenocarcinoma from (A) control group of rat and (B) RAFC group of rat
The examination of rats revealed a significant decrease in number of rats with mammary tumor (Figure 3), number of tumor/rat (Figure 4) and tumor volume by 54, 72 and 75% respectively in RAFC group compared to control group (Table II). Out of 50 rats in RAFC group, 17 had malignant tumors and 4 rats suffered from fibroadenomas. The tumor volume in these rats was very small. On the other hand, in control group all the 50 rats suffered from malignant tumors. Most of the rats had multiple tumors and the tumor volume was larger. The ibuprofen treated rats also showed significant decrease in number of rats with tumour, number of tumors per rat and smaller tumor volumes by 43, 55 and 59% respectively. Treatment of rats with RAFC also increased the latency period of tumor induction significantly. Median detection period (50% of tumors) was 92, 83 and 56 days respectively in the rats of RAFC, ibuprofen and control group respectively after DMBA induction (Table II).
Figure 3: Effects of RAFC and ibuprofen on breast cancer incidence. The control group received Teklad powdered chow diet, the RAFC group received chow plus 1,200 mg/kg RAFC, and the ibuprofen group received chow plus 1,200 mg/kg ibuprofen
Figure 4: Effects of RAFC and ibuprofen on tumor burden. The control group received Teklad powdered chow diet, the RAFC group received chow plus 1,200 mg/kg RAFC, and the ibuprofen group received chow plus 1,200 mg/kg ibuprofen
Table II: Effects of RAFC and ibuprofen on the number of rats with tumor, number of tumors per rat, and tumor volume after DMBA-induced rat mammary tumors
| Group | Latency period (days) | Number of rats with tumor (%) | Number of tumors per ratc | Tumor volume (cc)d | |
|---|---|---|---|---|---|
| Cancera | All tumors (cc)b | ||||
| Control | 58 | 100 | 100 | 3.2 ± 60.2 | 1.6 ± 0.4 |
| RAFC | 95f | 32 (68)e | 60 (40)e | 1.6 ± 0.3 (52)e | 0.7 ± 0.2 (57)e |
| Ibuprofen | 86f | 60 (40)e | 60 (40)e | 1.6 ± 0.3 (52)e | 0.7 ± 0.2 (57)e |
| aThe frequency of animals that developed breast cancer; bAll tumors includes animals in the RAFC treatment group that developed fibroadenomas; cMean number of tumors/animal 6 ± SE; dMean tumor volume 6 ± SE; eStatistical significance relative to the control group at p=0.001; Reductions in the incidence rates, tumor burden, and tumor volume for the experimental diets relative to the control diet are given in parentheses | |||||
The mean RAFC level in serum was 4.3 mg/mL. However, the level of RAFC in rats without tumor was slightly more (4.6 mg/mL) than those with tumor (4.1 mg/mL). The ibuprofen levels in serum ranged from 5–11 mg/mL.
Discussion
RA is used to treat breast cancer (Huang et al., 1988), head and neck cancer (Lehman et al., 1988), ovarian adenocarcinoma (Szuts et al., 1991), human malignant gliomas (Jeong et al., 2006), and acute promyelocytic leukemia (Chung et al., 2012). But its poor aqueous solubility (Crocetti et al., 2012; Tanaka et al., 2013) under in vivo limits its clinical applications. Since RAFC possesses more bioavailabity we devised an experiment to investigate the effect of RAFC in the treatment of mammary carcinogenesis. Our results demonstrate that RAFC is a potential chemopreventive agent against the development of chemically-induced breast cancer. The observed chemopreventive effects of the RAFC exceeded those of the ibuprofen. The exact mechanism by which RAFC suppresses mammary tumor is not clearly known but it works similar to that of ibuprofen. Treatment of animals with RAFC did not lead to any toxic effect.
The animals were palpated twice a week for detection of mammary tumors after 28 days of DMBA treatment. The clinical parameters like number of rats with tumor, time of first tumor appearance, number of tumors per rat, relative tumor size, and location of every tumor were recorded weekly. A micrometer caliper was used to measure tumor diameters from which tumor volumes were calculated using the formula V = 4/3Ï€r3. H & E staining was used for histological evaluation of the tumors and HPLC was used to determine the level of RAFC and ibuprofen in the serum of animals at completion of the experiment. All these results indicated that RAFC can act as effective therapeutic agent in the treatment of mammary carcinogenesis.
Conclusion
Administration of RAFC, suppressed the number of rats with tumor, number of tumors per rat, and volume of malignant breast tumors induced by DMBA in female rats. These results suggest that celecoxib may be an effective chemoprevention agent against human breast cancer.
References
Alshafie GA, Harris RE, Abou-Issa H, Robertson FM, Parrett ML, Ross M. Chemopreventive effects of ibuprofen and 4-HPR in the DMBA rat mammary tumor model. Anticancer Res. 1999; 19: 1-6.
Chung KD. Jeong Young-Il, Chung CW, Kim DH, Kang DH. Anti-tumor activity of all-trans retinoic acid-incorporated glycol chitosan nanoparticles against HuCC-T1 human cholangiocarcinoma cells. Int J Pharmaceut. 2012; 422: 454-61.
Crocetti E, Trama A, Stiller C, Caldarella A, et al. Epide¬miology of glial and non-glial brain tumors in Europe. Eur J Cancer. 2012; 48: 1532-42.
Defer GL, Adle-Biassette H, Ricolfi F, Martin L, Authier FJ, Chomienne C, Degos L, Degos J. All-trans retinoic acid in relapsing malignant gliomas: Clinical and radiological stabilization associated with the appearance of intratumoral calcifications. J Neurooncol. 1997; 34: 169-77.
Elston RC, Johnson WD. Essentials of biostatistics. 2nd ed. Philadelphia, FA, Davis Company, 1994.
Harris RE, Kasbari S, Farrar WB. Prospective study of non-steroidal drugs and breast cancer. Oncol Rep. 1999; 6: 71-73.
Harris RE, Namboodiri KK, Farrar WB. Epidemiologic study of non-steroidal anti-inflammatory drugs and breast cancer. Oncol Rep. 1995; 2: 591-92.
Harris RE, Namboodiri KK, Farrar WB. Non-steroidal anti-inflammatory drugs and breast cancer. Epidemiology 1996; 7: 203-05.
Huang EJ, Ye YC, Chen SR, Chai JR, Lu, JX, Zhoa L, Gu LJ, Wang ZY. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-72.
Jeong YI, Kim SH, Jung TY, Kim IY, et al. Polyion complex micelles composed of all-trans retinoic acid and poly(ethylene glycol)-grafted chitosan. J Pharm Sci. 2006; 95: 2348-60.
Joarder FS, Abou-Issa H, Robertson FM, Parrett ML, Alshafie GA, Harris RE. Growth arrest of DMBA-induced mammary carcinogenesis with ibuprofen treatment in female Sprague-Dawley rats. Oncol Rep. 1997; 4: 1271-73.
Krupitza G, Hulla W, Harant H, Dittrich E, Kallay E, Huber H. Retinoic acid induced death of ovarian carcinoma cells correlates with c-myc stimulation. Int J Cancer. 1995; 61: 649-59.
Lehman PA, Slattery JT, Franz TJ. Percutaneous absorption of retinoids: Influence of vehicle, light exposure, and dose. J Invest Dermatol. 1988; 91: 56-61.
Lee PP, Ip MM. Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase. Prostaglandins Leukotrienes Essent Fatty Acids. 1992; 45: 21-31.
McCormick DL, Madigan MJ, Moon RC. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res. 1985; 45: 1803-08.
Norden AD, Wen PY. Glioma therapy in adults. Neurologist 2006; 12: 279-92.
Robertson FM, Parrett ML, Joarder FS, Ross M, Abou-Issa HM, Alshafie G, Harris, RE. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett. 1998; 122: 165-75.
Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013; 63: 11-30.
Singletary ES, Bevers T, Dempsey P, Farrar WB, Garber J, Harris RE, Helvie M, Jacobs M, Pass H, Patterson-Smith ML, Tarantolo S, Venta LA. Screening for and evaluation of suspicious breast lesions. Oncology (Basel). 1998; 12: 89-138.
Stummer W, Kamp MA. The importance of surgical resection in malignant glioma. Curr Opin Neurol. 2009; 22: 645-49.
Szuts EZ, Harosi FI. Solubility of retinoids in water. Arch Biochem Biophys. 1991; 287: 297-304.
Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: No longer a dead end? Nat Rev Clin Oncol. 2013; 10: 14-26.
Weigelt B, Peterse JL, van‘t Veer LJ. Breast cancer metastasis: Markers and models. Nat Rev Cancer. 2005; 5: 591-602.
